OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Cohen on Efforts Needed to Unmet Needs in R/R Multiple Myeloma

June 2nd 2023

Adam D. Cohen, MD, discusses unmet needs and areas for future investigation within the relapsed/refractory multiple myeloma treatment landscape.

Dr Sokolova on Talazoparib Plus Enzalutamide in mCRPC

June 1st 2023

Alexandra Sokolova, MD, discusses key findings from the phase 3 TALAPRO-2 trial in patients with metastatic castration-resistant prostate cancer and unanswered questions regarding the use of PARP inhibitors plus androgen receptor inhibitors in patients with biomarker-negative disease.

Dr Hilton on Trastuzumab Deruxtecan in HER2+ Metastatic Breast Cancer

June 1st 2023

Christie J. Hilton, DO, discusses the first-line standard of care and changes in the second-line SOC, including key findings from the phase 3 DESTINY-Breast03 trial, in patients with HER2-positive metastatic breast cancer.

Dr Yuan on the Importance of Clinical Trial Enrollment in Breast Cancer

June 1st 2023

Yuan Yuan, MD, PhD, discusses the importance of clinical trial participation and enrollment in patients with breast cancer.

Dr Zonder on Ongoing Research at Karmanos Cancer Institute in Multiple Myeloma

June 1st 2023

Jeffery Zonder, MD, leader, multiple myeloma sub-committee, Barbara Ann Karmanos Cancer Institute, professor of medicine, Departments of Hematology and Oncology, Wayne State University School of Medicine, discusses ongoing research in multiple myeloma taking place at the Barbara Ann Karmanos Cancer Institute.

Dr Liu on the Importance of NGS Testing in NSCLC

June 1st 2023

Stephen V. Liu, MD, discusses the importance of next-generation sequencing in non–small cell lung cancer, and details trials that have continued to move this treatment arena forward.

Dr King on Teratoma in Residual Nonretroperitoneal Disease After Chemotherapy for Testicular Cancer

June 1st 2023

Jennifer M. King, MD, discusses results from a retrospective study on the prevalence of teratoma and active germ cell tumors in patients who have residual nonretroperitoneal disease following chemotherapy for nonseminomatous germ cell tumors, and what these findings indicate about the need for surgical resection in this patient population.

Dr Nayak on the Identification of Primary CNS Lymphoma

June 1st 2023

Lakshimi Nayak, MD, discusses the diagnosis of patients with primary CNS lymphoma.

Dr Kelley on the Need for Additional Second-line Therapies in Cholangiocarcinoma

June 1st 2023

R. Kate (Katie) Kelley, MD, discusses unmet needs and treatment challenges within the current standard-of-care for patients with cholangiocarcinoma.

Dr Santos on the Evolution of Osimertinib in EGFR Mutated NSCLC

May 31st 2023

Edgardo S. Santos, MD, FACP, discusses the evolution of osimertinib in the treatment of patients with EGFR-mutated non–small cell lung cancer and the updated data that reaffirmed its role in the adjuvant setting for this patient population.

Dr Katims on the Feasibility of scRNA-seq in FGFR3+ Upper Tract Urothelial Carcinoma

May 31st 2023

Andrew Katims, MD, MPH, discusses the feasibility of using single-cell RNA-sequencing in FGFR3-mutated upper tract urothelial carcinoma

Dr Wise on the Deciding Between Doublet and Triplet Regimens in Prostate Cancer

May 31st 2023

David R. Wise, MD, PhD, discusses considerations for the use of doublet or triplet regimens for the treatment of patients with prostate cancer.

Dr Armstrong on the FDA Approval of Abiraterone/Olaparib Combination in BRCA-mutated mCRPC

May 31st 2023

Andrew J. Armstrong, MD, MSc, discusses the significance of the FDA approval of olaparib plus abiraterone acetate and prednisone or prednisolone in patients with BRCA-mutated metastatic castration-resistant prostate cancer.

Dr Stone on the Investigation of Limited English Proficiency and PSA Screening Rates in Prostate Cancer

May 31st 2023

Benjamin V. Stone, MD, discusses clinical implications derived from a retrospective study on the effect of limited English proficiency on prostate-specific antigen screening rates in American men with prostate cancer, as well as the need to improve equitable access to PSA screening across academic and community centers.

Dr Callander on Ongoing and Future Clinical Trials in Multiple Myeloma at Carbone Cancer Center

May 31st 2023

Natalie S. Callander, MD, discusses several ongoing and planned clinical trials evaluating the use of novel therapeutic regimens in multiple myeloma.

Dr Katims on the Goal for Investigating the Immune Phenotype of FGFR3+ Upper Tract Urothelial Carcinoma

May 30th 2023

Andrew Katims, MD, MPH, discusses the rationale for investigating immune responses in the tumor microenvironment of FGFR3-mutated upper tract urothelial carcinoma using single-cell RNA-sequencing.

Dr Santos on the Impact of Cemiplimab With Chemotherapy in Squamous NSCLC

May 30th 2023

Edgardo S. Santos, MD, FACP, discusses the impact of treatment with cemiplimab plus chemotherapy in patients with squamous non–small cell lung cancer.

Dr Hilton on the Potential Impact of the CompassHER2-pCR Trial in HER2+ Breast Cancer

May 30th 2023

Christie J. Hilton, DO, discusses the potential impact of the ongoing phase 2 CompassHER2-pCR trial for patients with HER2-positive breast cancer.

Dr Girda on the Use of Pembrolizumab Plus Chemotherapy in Endometrial Cancer

May 30th 2023

Eugenia Girda, MD, FACOG, discusses the use of pembrolizumab plus chemotherapy for patients with endometrial cancer as seen in the phase 3 NRG-GY018 trial.

Dr. Tagawa on the Evolution and Selection of PARP Inhibitors in mCRPC

May 30th 2023

Scott Tagawa, MD, MS, FACP, discusses the evolution of PARP inhibitor use in metastatic castration-resistant prostate cancer and available PARP inhibitors for molecularly-selected patients in this space.